[Form 4] Zomedica Corp. Insider Trading Activity

Rhea-AI Filing Summary

Kevin Klass, Senior Vice President of Sales at Zomedica Corp., reported acquiring 500,000 shares of common stock on 08/08/2025 at $0.04 per share under transaction code P (pursuant to a written plan). Following this transaction his reported beneficial ownership is 3,700,030 shares, held directly.

Positive

• Insider acquisition: Kevin Klass acquired 500,000 shares of Zomedica common stock.
• Low purchase price disclosed: Transaction price reported at $0.04 per share.
• Post-transaction ownership: Beneficial ownership increased to 3,700,030 shares (direct).
• Transaction code P indicates the purchase was made pursuant to a written plan (10b5-1).

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchase of 500,000 shares at $0.04 raises direct ownership to 3.7M; transaction executed under a written plan.

The Form 4 discloses a non-derivative acquisition by Kevin Klass on 08/08/2025: 500,000 common shares purchased at $0.04 per share under code P, which typically denotes a transaction under a written plan. The filing reports 3,700,030 shares beneficially owned following the transaction. On its own, this is a clear insider purchase disclosure but its market significance depends on company capitalization and context not provided in the form.

Corporate Governance Expert

TL;DR: Insider followed a documented plan (code P) to acquire 500K shares; disclosure meets Section 16 reporting requirements.

The report identifies the reporting person, role (Senior Vice President of Sales), transaction date, security type, number of shares acquired, price per share, and post-transaction beneficial ownership. The use of transaction code P indicates the acquisition was made pursuant to a plan intended to provide 10b5-1 affirmative defense conditions. The Form 4 appears to be a routine, compliant insider disclosure without additional qualifiers or disclaimers.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klass Russell Kevin

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE, STE 100

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr Vice President of Sales

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	08/08/2025		P		500,000	A	$0.04	3,700,030	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kevin Klass	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZOM file on this Form 4?

The Form 4 reports that Kevin Klass, Sr. Vice President of Sales, acquired 500,000 common shares of Zomedica on 08/08/2025.

At what price were the ZOM shares purchased?

The reported purchase price was $0.04 per share.

How many ZOM shares does Kevin Klass beneficially own after the transaction?

Following the reported transaction, he beneficially owns 3,700,030 shares (reported as direct ownership).

What does transaction code P mean on the ZOM Form 4?

Transaction code P is used to indicate the transaction was made pursuant to a written plan, consistent with 10b5-1 affirmative defense conditions.

What is Kevin Klass's role at Zomedica as reported on the Form 4?

He is reported as Senior Vice President of Sales and is the reporting person on the Form 4.